Dopamine-restoring drugs already used to treat Parkinsonâ€™s disease may also be beneficial for the treatment of diabetic retinopathy, a leading cause of blindness in adults, researchers have discovered. The results were published recently in Journal of Neuroscience.
Diabetic retinopathy affects more than a quarter of adults with diabetes and threatens the vision of more than 600,000 people in the United States. Doctors had previously thought most of the impairment of vision in diabetic retinopathy came from damage to the blood vessels induced by high blood sugar, but had known that dopamine, a vital neurotransmitter in the brain, was also important in the retina.
â€œThere was some evidence already that dopamine levels were reduced in diabetic retinopathy, but whatâ€™s new here is: we can restore dopamine levels and improve visual Ray Ban outlet function in an animal model of diabetes,â€ says Machelle Pardue, PhD, associate professor of ophthalmology at Emory University School of Medicine and research career scientist at the Atlanta VA Medical Center. Read more
Vision loss can affect oneâ€™s daily function and quality of life (QOL), but few research studies have actually looked at the impact of visual impairments on childrenâ€™s quality of life.
An Emory project aims to develop an instrument that will measure the effect of vision loss on the quality of life of children age 8 to 18.
Pictured from left to right: J. Devn Cornish, MD, professor and vice chair, Department of Pediatrics, Emory University School of Medicine; Andy Lovas, grand recorder, Knights Templar Eye Foundation; Sheila Angeles-Han, MD, MSc, assistant professor, Pediatric Rheumatology and Immunology, Emory University School of Medicine; Larry Vogler, MD, division chief, Pediatric Rheumatology and Immunology, Emory University School of Medicine; and Tim Taylor, director of marketing, Knights Templar Eye Foundation
The project is being led by Emory pediatric rheumatologist Sheila Angeles-Han, MD, MSc. Han recently received a $40,000 grant from the Knights Templar Eye Foundation to augment her work in this area. She is collaborating with pediatric ophthalmologists at the Emory Eye Center.
Currently, there are no validated questionnaires or tools to determine how children in these age groups cope with their visual impairments and the impact of vision loss on their daily lives. This knowledge can enhance physiciansâ€™ understanding of diseases that affect vision.
Drawing shows areas of the eye
Emory Eye Center researchers are looking at the role of the immune system in the inflammation of the eye and the progression of eye diseases.
Santa Ono, PhD, professor of ophthalmology, Emory School of Medicine and researcher at the Emory Eye Center, and Emory senior vice provost for undergraduate education and academic affairs, and his team at the R. Howard Dobbs Jr. Ocular Immunology Lab, focus on the immune component of age-related macular degeneration (AMD), ocular cancer (melanoma and retinoblastoma) and ocular inflammation.
Santa J. Ono, PhD
Macular degeneration is the leading cause of sight impairment and blindness in older people. The macula, in the center of the retina, is the portion of the eye that allows for the perception of fine detail. AMD gradually destroys a personâ€™s central vision, ultimately preventing reading, driving, and seeing objects clearly
In a recent article of Emory Magazine, Ono, an ocular immunologist, says, â€œIf a person with AMD looks at graph paper, some of the lines will be wavy instead of straight. Certain parts of the image are no longer being transferred to the brain.â€